Biogen, Inc. (BIIB)
$229.44 2.11 (0.91%)
16:04 EDT BIIB Stock Quote Delayed 15 Minutes
Previous Close $231.55
Market Cap 48.41B
PE Ratio 16.39
Volume (Avg. Vol.) 832,811
Day's Range 229.35 - 231.99
52-Week Range 216.12 - 388.67
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
- From InvestorPlace
- From the Web
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Biogen earnings for the first quarter of 2019 have BIIB stock down on Wednesday despite it beating it estimates for the period.
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Regardless of political risks, there are still valuable opportunities in some healthcare stocks. Here are three to consider.
BIIB stopping its Alzheimer's trials hurt. But for long-term investors, the dip has opened up an opportunity in Biogen stock
The stock charts of T, LOW and MS merit some close technical scrutiny before the trading week comes to a close. Here's what you need to know.
Biogen news about the company's decision to discontinue two Phase 3 Alzheimer’s drug studies is hitting BIIB stock hard on Thursday.
Nightstar Therapeutics stock was soaring on Monday following news that Biogen (BIIB) is acquiring the company for $877 million.
Mizuho Securities has challenged each analyst to select long-term stocks that can provide value. Here are 7 of their top stock picks.
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
These pharma stocks offer low multiples and growth catalysts that could offer relief to investors in the coming year.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
From Market News Video
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Costco Wholesale Corp (COST), where a total of 17,258 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 107.2% of COST's average daily trading volume over the past month of 1.6 million shares..
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!